Get started
Author

Antoine Bessou

Observed name: A. Bessou
ORCID: 0009-0000-8770-426X
Observed ORCID: 0009-0000-8770-426X
OpenAlex ID: A5037920967
Behavioural and sleep issues after initiation of elexacaftor–tezacaftor–ivacaftor in preschool-age children with cystic fibrosis
2024 · I Sermet-Gaudelus, Sihem Benaboud, et al. · The Lancet · 29
PDF
Effect of elexacaftor–tezacaftor–ivacaftor on bronchial dilatations in adolescents with cystic fibrosis: a multicentre prospective observational study
2025 · Isabelle Sermet-Gaudelus, Alexia Letierce, et al. · The Lancet Respiratory Medicine · 22
Epidemiology of Lyme Borreliosis in France in Primary Care and Hospital Settings, 2010–2019
2023 · Charles Nuttens, Antoine Bessou, et al. · Vector-Borne and Zoonotic Diseases · 17
PDF
Survival outcomes for patients with multiple myeloma in France: A retrospective cohort study using the Système National des Données de Santé national healthcare database
2023 · Xavier Leleu, Boris Gorsh, et al. · European Journal Of Haematology · 15
PDF
Weight Telemonitoring of Heart Failure Versus Standard of Care in a Real-World Setting: Results on Mortality and Hospitalizations in a 6-Month Nationwide Matched Cohort Study
2024 · François Roubille, Grégoire Mercier, et al. · European Journal of Heart Failure · 9
Assessing the treatment pattern, health care resource utilisation, and economic burden of multiple myeloma in France using the Système National des Données de Santé (SNDS) database: a retrospective cohort study
2022 · Antoine Bessou, Xavier Colin, et al. · The European Journal of Health Economics · 9
PDF
Monitoring outpatient antibiotic utilization using reimbursement and retail sales data: a population-based comparison in France, 2012–17
2021 · Nhung T. H. Trinh, Martin Chalumeau, et al. · Journal of Antimicrobial Chemotherapy · 9
Evolution of Lyme Borreliosis Epidemiology in Primary Care and Hospital Settings in France During the COVID-19 Pandemic
2024 · Charles Nuttens, Stéphanie Duret, et al. · Vector-Borne and Zoonotic Diseases · 4
PDF
Two-year management after renal transplantation in 2013 in France: Input from the French national health system database
2018 · Philippe Tuppin, Antoine Bessou, et al. · Néphrologie & Thérapeutique · 3
Clinical characteristics and outcomes in the adult cystic fibrosis population in Europe from 2014 to 2024: analysis of the European Cystic Fibrosis Society Patient Registry
2026 · Annalisa Orenti, Kris De Boeck, et al. · The Lancet Respiratory Medicine · 1
A disrupted microbial network and an ecological shift towards anaerobes in NTM-infected cystic fibrosis patients
2026 · Hélène Pailhoriès, Lourdes Velo-Suarez, et al. · Journal of Cystic Fibrosis · 1
PDF
Impact of Elexacaftor-Tezacaftor-Ivacaftor on fungal colonisation in children and adolescents with cystic fibrosis
2026 · Emilie Sitterlé, Anne-Sophie Bonnel, et al. · Journal of Cystic Fibrosis · 1
Survie des patients atteints de myélome multiple en France entre 2013 et 2019 : données de vie réelle issues du Système national des données de santé (SNDS)
2022 · X. Leleu, B. Gorsh, et al. · Revue d Épidémiologie et de Santé Publique · 1
P943: Survival Outcomes of Patients With Multiple Myeloma in France: a Cohort Study Using the French National Healthcare Database (snds)
2022 · X. Leleu, B. Gorsh, et al. · HemaSphere · 1
Estimation du fardeau direct et indirect de la grippe en France de la saison 2010/2011 à la saison 2017/2018 : analyse épidémiologique et économique à partir du Programme de médicalisation des systèmes d’information
2020 · F. Fouad, A. Bessou, et al. · Revue d Épidémiologie et de Santé Publique · 1
Longitudinal change in FEV1 in adults with cystic fibrosis treated with elexacaftor–tezacaftor–ivacaftor in France: a prospective observational study
2026 · Pierre-Régis Burgel, Alexandre Lafourcade, et al. · The Lancet Respiratory Medicine
Effects of air pollution on pulmonary exacerbations: longitudinal analysis of the CF registry
2026 · Michelle Leemans, Ralph Epaud, et al. · European Respiratory Journal
Unsupervised multidimensional phenotyping reveals environmental influences on cystic fibrosis disease trajectories
2026 · Michelle Leemans, Ralph Epaud, et al. · European Respiratory Journal
Continuous glucose monitoring to track metabolic changes in youths with cystic fibrosis before and after initiation of elexacaftor/tezacaftor/ivacaftor therapy
2026 · Alfonso Galderisi, Hadija Marchiori, et al. · The Journal of Clinical Endocrinology & Metabolism
Adherence patterns and their determinants to CFTR modulators in France
2026 · Oriane Talabart, Elia Eid, et al. · Respiratory Medicine
PDF
Effects of air pollution on pulmonary exacerbations: longitudinal analysis of the CF registry
2026 · M. Leemans, R. Epaud, et al. · Journal of Cystic Fibrosis
Characterization of pwCF with two non responsive CFTR variants to modulators and assessment of their potential for inclusion in CF clinical trials
2026 · R. Chiron, A. Coudrat, et al. · Journal of Cystic Fibrosis
Unsupervised multidimensional phenotyping reveals environmental influences on cystic fibrosis disease trajectories
2026 · M. Leemans, R. Epaud, et al. · Journal of Cystic Fibrosis
Persistent decline in FEV1 in adults with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor
2026 · P.-R. Burgel, A. Lafourcade, et al. · Journal of Cystic Fibrosis
SOLAR: a noninterventional study of outcomes over the long term of people with cystic fibrosis (CF) aged ≥6 years treated with elexacaftor/tezacaftor/ivacaftor using data from the French CF Registry
2026 · Conor Daly, Pierre-Régis Burgel, et al. · ERJ Open Research
Works count: 39
Citation count: 123
H-index: 7
I10-index: 4
Year
Topic
Type